Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk MDS or AML (PANOBEST)

Trial Profile

Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk MDS or AML (PANOBEST)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms PANOBEST
  • Most Recent Events

    • 01 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 23 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.
    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top